Galderma Brings 22 Abstracts to AAD 2026, Including Nemluvio's 104-Week Safety and Trifarotene Data
Galderma presented 22 abstracts at the American Academy of Dermatology (AAD) annual meeting held in Denver from March 27-31, 2026. The portfolio includes late-breaking data, oral presentations, and nine dermatology skincare presentations. The data clusters around three axes. Nemluvio (atopic dermatitis), AKLIEF (acne), and Cetaphil (skincare).
Nemluvio’s 104-week long-term safety data
The most-watched announcement was Nemluvio’s (nemolizumab) 104-week long-term safety dataset. Nemluvio is a monoclonal antibody blocking the IL-31 receptor, targeting chronic itch in atopic dermatitis patients. Two years of safety data is decisive for clinical prescribing.
Three analyses were presented at the meeting.
Pediatric pharmacokinetic, safety, and efficacy late-breaking data: Atopic dermatitis has particularly high incidence in pediatric populations, but pediatric prescribing data lags adult data. Late-breaking publication enables updates to pediatric prescribing standards.
Adolescent efficacy data: Examines how the efficacy profile in adolescents differs from adult data.
Post-week-16 partial/minimal responder analysis: Patients with partial or minimal response at week 16 were analyzed separately to identify which variables convert non-responders into responders.
Together, these three analyses sharpen target patient selection and assessment timing for Nemluvio prescribing.
AKLIEF, clinical data on a fourth-generation retinoid
AKLIEF (trifarotene) cream is Galderma’s “fourth-generation retinoid” for acne. Trifarotene selectively activates the RAR-gamma receptor, producing a profile with less skin irritation than earlier retinoids (retinoic acid, adapalene, tazarotene).
Four posters were presented at this meeting. One examined real-world clinical results in Indian patients with facial and truncal acne. Another summarized real-world evidence on customized regimen combinations (trifarotene plus other actives).
The “fourth-generation retinoid” framing carries clear meaning. From the first-generation retinoic acid through second-generation adapalene to third-generation tazarotene, trifarotene refines toward maintaining efficacy while reducing skin irritation. Korean acne prescribing standards likely shift toward trifarotene within five years.
Five Cetaphil e-posters
Galderma’s consumer line, Cetaphil, presented five e-posters. Topics included onset of itch relief, mature skin efficacy, and cleanser mildness.
The mature skin analysis targets pre- and postmenopausal women. The format quantifies how cleanser pH, surfactant type, and residual moisturizing ingredients affect the epidermal barrier. This thread connects to Olay’s cell adhesion research the same quarter. Cleansers are being redefined from “cleansing tools” to “tools for preserving epidermal barrier proteins.”
One AI-driven oral presentation
A notable presentation used AI to identify sensitive skin risk factors, presented in oral format. This signals AI tools moving past simple image analysis into risk-factor identification in dermatology practice.
Another oral abstract addressed acne management following isotretinoin therapy. Isotretinoin is the curative option for severe acne, but post-treatment recurrence management lacked standardized guidelines. This presentation aims to fill that gap.
Industry implication
Two industry messages emerge from Galderma’s announcement. First, other major dermatology companies (Kenvue with Neutrogena and Aveeno) also released large datasets at AAD 2026 the same quarter. Spring has become the concentration point for dermatology clinical data.
Second, the pattern of prescription drugs (Nemluvio, trifarotene) and consumer skincare (Cetaphil) being announced at the same conference by the same company is settling in. As the boundaries between prescription, OTC, and cosmetic blur, the trend toward integrated company-wide data within a single firm is firming up.